Evidence map›Paper›PMID 34401289›Full record

ArticleRespiratory medicine case reports2021

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report.

Yozo Sato, Akimasa Sekine, Eri Hagiwara, Midori Sato, Takafumi Yamaya, Masato Asaoka, Katsuyuki Higa, Satoshi Ikeda, Tomohisa Baba, Shigeru Komatsu and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yozo SatoDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Akimasa SekineDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Eri HagiwaraDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Midori SatoDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Takafumi YamayaDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Masato AsaokaDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Katsuyuki HigaDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Satoshi IkedaDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Tomohisa BabaDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Shigeru KomatsuDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Tae IwasawaDepartment of Radiology, Kanagawa Cardiovascular and Respiratory Center, Japan.
Takashi OguraDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan.
Kanagawa Cardiovascular and Respiratory Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, we report the case of an 84-year-old woman with epidermal growth factor receptor (

Indexed as

AfatinibDrug-induced interstitial lung disease (ILD)EGFRLung adenocarcinomaOsimertinib

Identifiers

PMID34401289
PMCPMC8349001
OpenAlexW3177017317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.